Mumbai multiplexes entered Sunday with two kinds of demand on the same weekend: a new Hindi fantasy film with a strong mass-market opening, and a 2019 Marvel title that still sells premium seats. Avengers: Endgame's re-release is doing the heavier lifting on high-price booking sheets, while Vvaan is posting the kind of two-day number that would normally own the entertainment conversation.
HT's box-office report put Vvaan's Day 2 net at roughly ₹11 crore, taking its two-day India net past ₹19 crore. That is a healthy start for a Hindi fantasy release starring Sidharth Malhotra and Tamannaah Bhatia. But the number also explains why the booking-share story matters more in Mumbai: a film can post a big total while losing the most expensive shows to a re-release.
The premium-seat question
In Mumbai, the difference between a good weekend and a great one often sits in a handful of large-format screens. IMAX, 4DX, Dolby and premium recliner auditoriums carry higher ticket prices, and their occupancy moves the needle for exhibitors. Endgame's re-release is built for those screens. It has a known fan base, a nostalgia cycle, and a runtime-and-spectacle proposition that justifies the premium ticket. The film's original release was an event; the re-release turns that event into a repeatable weekend product.
Vvaan, by contrast, is a new Hindi title. Its audience is broader and more spread out. It can draw families, single-screen audiences, and viewers who are not chasing a premium format. That is not a weakness. It is a different distribution pattern. The Hindi film may win on total footfalls across the city while the Marvel re-release wins on revenue per seat in the top-tier multiplexes.
Who pays for the window
The exhibitor pays first. Every premium show given to Endgame is a premium show not given to Vvaan or another new release. In a market where screen space is finite, that is a real cost. The distributor of the Hindi film pays in another way: marketing spend has to work harder when the best slots are fragmented. The audience pays at the counter, where a family of four can spend several times more for a large-format ticket than for a standard show.
The re-release's economics are also different. Endgame has already recovered its production and marketing costs in its original run. A re-release adds revenue with limited new spend. That makes it an attractive scheduling tool for multiplexes: lower risk, high yield on premium screens, and a known advance-booking curve. For a new Hindi film, the same screen is an investment in a fresh IP. The clash is therefore not just Endgame versus Vvaan. It is catalog IP versus new Hindi content for the most valuable real estate in the multiplex.
What the audience gets
For Marvel fans in Mumbai, the weekend offers a rare second look at Endgame on the biggest available screens. For Hindi audiences, Vvaan is available across a wider set of theatres and showtimes. The two audiences are not identical, and that is why both can coexist. The friction appears in the premium tier, where the overlap is greatest.
The booking share also tells exhibitors what to do next weekend. If Endgame's re-release holds premium occupancy, more catalog titles could return for limited windows. If Vvaan's mass-market pull keeps growing, exhibitors may rebalance toward the Hindi film's evening shows. The decision will be made show by show, not by the headline two-day gross.
That is the useful way to read the weekend. Vvaan's ₹19 crore two-day India net is a strong data point, but it is not the whole Mumbai story. The city's multiplex booking pattern shows a re-release taking the expensive seats while a new Hindi fantasy film builds its own audience elsewhere. The winner depends on what the exhibitor is measuring: total admissions, premium yield, or the value of a fresh Hindi release in a market that still runs on theatrical windows.